Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients
- PMID: 7886650
- PMCID: PMC473709
- DOI: 10.1136/thx.50.1.54
Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients
Abstract
Background: There is controversy as to the relative safety of fenoterol and salbutamol. No differences have been found in the relative cardiac beta 1/beta 2 receptor activity of inhaled fenoterol and salbutamol in normal subjects. These initial findings have been extended by comparing the respective potencies of equivalent doses by weight of fenoterol and salbutamol in asthmatic subjects, in terms of airways and systemic responses.
Methods: Eighteen asthmatic patients of mean (SD) age 40 (14) years and a forced expiratory volume in one second (FEV1)% predicted of 56 (14)% (1.97 (0.66)1) were randomised to inhale fenoterol (100 micrograms/puff or 200 micrograms/puff), salbutamol, or placebo (100 micrograms/puff or 200 micrograms/puff) on three separate days. Dose-response curves were constructed using cumulative doses of 100 micrograms, 200 micrograms, 400 micrograms, 1000 micrograms, 2000 micrograms, and 4000 micrograms, and airways and systemic responses were measured 20 minutes after each dose with 40 minute increments. Dose ratios for the relative potency of fenoterol versus salbutamol were calculated from the dose-response curves using regression analysis of parallel slopes.
Results: There was no difference in bronchodilator potency between fenoterol and salbutamol (as median dose ratio): FEV1 1.1 (95% CI 0.4 to 4.6). In contrast, dose ratios for systemic responses showed that fenoterol was more potent than salbutamol: serum potassium 3.7 (95% CI 2.0 to 6.0), tremor 5.7 (95% CI 1.4 to 10.2), heart rate 1.6 (95% CI 1.0 to 2.3). At a conventional dose of 200 micrograms the only difference in response between the two drugs was observed for tremor (as mean difference): 0.23 log units (95% CI 0.06 to 0.41 log units).
Conclusions: There was no difference in the bronchodilator potency between fenoterol and salbutamol on a microgram equivalent basis. In contrast, systemic potency was greater with fenoterol, although this difference was not clinically relevant at conventional dosages up to 200 micrograms.
Similar articles
-
Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma.Chest. 1996 Sep;110(3):595-603. doi: 10.1378/chest.110.3.595. Chest. 1996. PMID: 8797398 Clinical Trial.
-
Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.Thorax. 1995 Jan;50(1):62-6. doi: 10.1136/thx.50.1.62. Thorax. 1995. PMID: 7886652 Free PMC article. Clinical Trial.
-
Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.Chest. 1994 Jun;105(6):1738-42. doi: 10.1378/chest.105.6.1738. Chest. 1994. PMID: 8205869 Clinical Trial.
-
Dose-response of inhaled drugs in asthma. An update.Clin Pharmacokinet. 1997 Jan;32(1):58-74. doi: 10.2165/00003088-199732010-00003. Clin Pharmacokinet. 1997. PMID: 9012556 Review.
-
Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects.Pharmacotherapy. 1985 May-Jun;5(3):109-26. doi: 10.1002/j.1875-9114.1985.tb03409.x. Pharmacotherapy. 1985. PMID: 2991865 Review.
Cited by
-
Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebuliser (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics.Br J Clin Pharmacol. 2005 Jan;59(1):5-13. doi: 10.1111/j.1365-2125.2005.02168.x. Br J Clin Pharmacol. 2005. PMID: 15606434 Free PMC article. Clinical Trial.
-
Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.Curr Opin Pulm Med. 2010 Jan;16(1):1-5. doi: 10.1097/MCP.0b013e328333def8. Curr Opin Pulm Med. 2010. PMID: 19887938 Free PMC article. Review.
-
Risk of severe life threatening asthma.Thorax. 1996 Nov;51(11):1073. doi: 10.1136/thx.51.11.1073. Thorax. 1996. PMID: 8958886 Free PMC article. No abstract available.
-
Effects of airway calibre on lung delivery of nebulised salbutamol.Thorax. 1997 Dec;52(12):1036-9. doi: 10.1136/thx.52.12.1036. Thorax. 1997. PMID: 9516895 Free PMC article.
-
Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.Thorax. 1996 Jan;51(1):54-8. doi: 10.1136/thx.51.1.54. Thorax. 1996. PMID: 8658370 Free PMC article. Clinical Trial.